Literature DB >> 31338909

Do the 2015 Beers Criteria predict medication-related harm in older adults? Analysis from a multicentre prospective study in the United Kingdom.

Nikesh Parekh1,2, Khalid Ali1,2, J Graham Davies3, Chakravarthi Rajkumar1,2.   

Abstract

PURPOSE: To investigate whether inappropriate prescribing, defined by the Beers Criteria, is associated with medication-related harm (MRH), hospital admission, and mortality in older adults in England.
METHODS: A multicentre, prospective cohort study recruited 1280 patients (median age 82 years) at hospital discharge. Patients were followed-up in the community by pharmacists for 8 weeks to identify MRH (harm from adverse drug reactions, non-adherence, and medication errors) and hospital admissions. One-year mortality was determined using hospital records. Potentially inappropriate medications (PIMs) were determined using the 2015 version of the Beers criteria. Logistic regression was used to investigate the relationship between patients prescribed PIMs and adverse outcomes.
RESULTS: Two hundred and seventy-six patients (22%) were prescribed one or more PIMs at hospital discharge. The main PIM classes prescribed at hospital discharge were benzodiazepines and related drugs (30%) and antidepressants (27%). 1116 out of 1280 patients completed follow-up and 413 (37%) experienced MRH. In 51 cases (12%), MRH was attributable to a PIM. There was no significant relationship between patients prescribed PIMs and overall MRH, hospital readmission or all-cause one-year mortality. Multiple PIMs at discharge was independently associated with an increased risk of ADR (OR 2.32, 95% CI 1.03-5.23).
CONCLUSION: The prescribing of PIMs is common at hospital discharge of older adults in England. The 2015 Beers criteria have a limited clinical value to predict adverse outcomes following hospital discharge in this setting.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Beers Criteria; hospital discharge; inappropriate prescribing; medication harm; older adults; pharmacoepidemiology

Mesh:

Year:  2019        PMID: 31338909     DOI: 10.1002/pds.4849

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Association Between Potentially Inappropriate Medications and 30-Day Post-Hospital Discharge Outcomes in US Veterans.

Authors:  Heather G Allore; Danijela Gnjidic; Melissa Skanderson; Ling Han
Journal:  Ann Pharmacother       Date:  2021-07-20       Impact factor: 3.154

2.  REview of potentially inappropriate MEDIcation pr[e]scribing in Seniors (REMEDI[e]S): French implicit and explicit criteria.

Authors:  Barbara Roux; Julie Berthou-Contreras; Jean-Baptiste Beuscart; Marion Charenton-Blavignac; Jean Doucet; Jean-Pascal Fournier; Blandine de la Gastine; Sophie Gautier; Régis Gonthier; Valérie Gras; Muriel Grau; Pernelle Noize; Elisabeth Polard; Karen Rudelle; Marie-Blanche Valnet-Rabier; Thomas Tannou; Marie-Laure Laroche
Journal:  Eur J Clin Pharmacol       Date:  2021-06-11       Impact factor: 2.953

Review 3.  Polypharmacy Management in the Older Adults: A Scoping Review of Available Interventions.

Authors:  M Kurczewska-Michalak; P Lewek; B Jankowska-Polańska; A Giardini; N Granata; M Maffoni; E Costa; L Midão; P Kardas
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

4.  A machine learning-based risk warning platform for potentially inappropriate prescriptions for elderly patients with cardiovascular disease.

Authors:  Wu Xingwei; Chang Huan; Li Mengting; Qin Lv; Zhang Jiaying; Long Enwu; Zhu Jiuqun; Tong Rongsheng
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 5.  Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: A systematic review and meta-analysis.

Authors:  Alemayehu B Mekonnen; Bernice Redley; Barbora de Courten; Elizabeth Manias
Journal:  Br J Clin Pharmacol       Date:  2021-05-18       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.